Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Goodwill: 2013-2025

Historic Goodwill for Amphastar Pharmaceuticals (AMPH) over the last 10 years, with Sep 2025 value amounting to $3.4 million.

  • Amphastar Pharmaceuticals' Goodwill rose 4.55% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 4.55%. This contributed to the annual value of $3.0 million for FY2024, which is 5.19% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Goodwill of $3.4 million as of Q3 2025, which was up 0.21% from $3.4 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Goodwill peaked at $3.8 million during Q2 2021, and registered a low of $2.9 million during Q3 2022.
  • In the last 3 years, Amphastar Pharmaceuticals' Goodwill had a median value of $3.2 million in 2023 and averaged $3.2 million.
  • Its Goodwill has fluctuated over the past 5 years, first dropped by 20.47% in 2022, then grew by 8.57% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Goodwill (Quarterly) stood at $3.3 million in 2021, then dropped by 5.64% to $3.1 million in 2022, then climbed by 2.88% to $3.2 million in 2023, then fell by 5.19% to $3.0 million in 2024, then rose by 4.55% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $3.4 million for Q2 2025, and $3.2 million during Q1 2025.